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Human coxsackievirus A6 (CVA6) is an enterically transmitted enterovirus. Until recently, CVA6
infections were considered as being of minor clinical significance, and only rarely aetiologically
linked with hand, foot and mouth disease (HFMD) associated with other species A enteroviruses
(particularly EV71 and CVA16). From 2008 onwards, however, CVA6 infections have been
associated with several outbreaks worldwide of atypical HFMD (aHFMD) accompanied by a
varicelliform rash. We recently reported CVA6-associated eczema herpeticum occurring
predominantly in children and young adults in Edinburgh in January and February 2014. To
investigate genetic determinants of novel clinical phenotypes of CVA6, we genetically
characterized and analysed CVA6 variants associated with eczema herpeticum in Edinburgh in
2014 and those with aHFMD in CAV isolates collected from 2008. A total of eight recombinant
forms (RFs) have circulated worldwide over the past 10 years, with the particularly recent
appearance of RF-H associated with eczema herpeticum cases in Edinburgh in 2014.
Comparison of phylogenies and divergence of complete genome sequences of CVA6 identified
recombination breakpoints in 2A–2C, within VP3, and between 59 untranslated region and VP1. A
Bayesian temporal reconstruction of CVA6 evolution since 2004 provided estimates of dates and
the actual recombination events that generated more recently appearing recombination groups
(RF-E, -F, -G and -H). Associations were observed between recombination groups and clinical
presentations of herpangina, aHFMD and eczema herpeticum, but not with VP1 or other structural
genes. These observations provided evidence that NS gene regions may potentially contribute to
clinical phenotypes and outcomes of CVA6 infection.
INTRODUCTION
Human coxsackievirus A6 (CVA6) is a member of the genus
Enterovirus in the family Picornaviridae, a group of primar-
ily enteric RNA viruses that cause a wide range of diseases
in humans and other mammals (Knowles et al., 2012).
There are currently .100 recognized human enterovirus
serotypes, classified into four species (EV-A to -D). EV-A
species are widely distributed in human and non-human
primate populations, and those infecting humans currently
comprise a total of 20 (sero)types. Of these, EV71 and
CAV16 are the most closely linked to hand, foot and
mouth disease (HFMD), occasionally leading to fatal menin-
goencephalitis (Solomon et al., 2010).
By contrast, although widely circulating in the community,
CVA6 has rarely attracted clinical attention as infections
are typically mild or asymptomatic. However, a change in
its clinical phenotype was reported in 2008, following the
discovery of a large outbreak of HFMD associated with
CVA6 in Finland (O¨sterback et al., 2009). Since then,
numerous case and surveillance reports have documented
substantial increases in HFMD incidence in Europe, Asia
and the USA, in each case strongly associated with CVA6
infections, and eclipsing EV71 and CAV16 as causative
agents (Chen et al., 2012; Chung et al., 2013; Di et al., 2014;
Feder et al., 2014; Fujimoto et al., 2012; Huang et al., 2013;
The GenBank/EMBL/DDBJ accession numbers for the CVA6
sequences are KP129335–KP129394 and KP144339–KP144353.
One supplementary table and two supplementary figures are available
with the online Supplementary Material.
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Kar et al., 2013; Kobayashi et al., 2013; Lo et al., 2011; Lu
et al., 2012; Mathes et al., 2013; Montes et al., 2013; Puenpa
et al., 2014; Sinclair et al., 2014; Wei et al., 2011; Yasui et al.,
2013). Moreover, several of these studies recorded differ-
ences in symptomatology from HFMD disease arising from
EV71 and CVA16 infections; CVA6-associated atypical
HFMD (aHFMD) is frequently associated with crusted
lesions, an eczema-form rash affecting the arms, trunk,
buttocks and legs, onychomadesis (nail loss), and a greater
disease severity than HFMD associated with other EV-A
serotypes (Chung et al., 2013; Mathes et al., 2013; Yasui
et al., 2013). One study from Thailand also described
frequent associations with high fever (Puenpa et al., 2014).
We recently reported a cluster of clinically presenting CVA6
infections in January and February 2014 in Edinburgh
(Sinclair et al., 2014). In these, hospitalized cases presented
with a rash diagnosed as eczema herpeticum by dermatolo-
gists and initially leading to clinical diagnoses of severe,
disseminated herpes simplex virus infections. The erythe-
matous papular rash involved the face, trunk and limbs, and
was followed by the appearance of vesicles and bullae.
Sequence analysis of the VP1 gene demonstrated that most
variants associated with the outbreak were genetically
distinct from other previously characterized CVA6 strains,
including those associated with all previous outbreaks of
aHFMD since 2008 and all earlier isolates.
The underlying reasons for these changes in clinical pheno-
type of CVA6 are unknown. Host factors, such as herd
immunity and age of infection, are known to influence
outcomes of enterovirus infections, but the evidence for its
rapid emergence worldwide argues strongly against popu-
lation-wide changes in host disease susceptibility to CVA6. To
investigate whether virus-specific factors were involved, we
genetically analysed CVA6 variants associated with the recent
Edinburgh aHFMD cases and those associated with the earlier
outbreak in Finland in 2008 in multiple gene regions. In
addition, complete genome sequences were obtained from 15
CVA6 strains. Two novel recombinant forms (RFs) of CVA6,
defined by phylogeny relationships in the non-structural (NS)
gene region, were identified that were associated specifically
with the recent aHFMD cases in Edinburgh (RF-H) and
previous outbreaks (RF-A). Although we lack the experi-
mental models to precisely identify determinants of virus
pathogenicity in human enterovirus infections, these observa-
tions provide evidence for a role of virus recombination in
the emergence of new CVA6 strains with altered clinical
phenotypes.
RESULTS
CAV-6 variants associated with aHFMD and
eczema herpeticum
All 10 of the patients with eczema herpeticum presenting
in 2014 in Edinburgh were infected with CVA6 variants
that were phylogenetically distinct from other previously
characterized variants of that serotype in the VP1 region
(Sinclair et al., 2014). An extended comparison in the VP1
region was performed using further samples collected before
the outbreak in Edinburgh (n516) and several CVA6
variants associated with the outbreak of aHFMD in Finland
in 2008 (n515; Fig. 1a). Despite the inclusion of these
additional sequences, the separate grouping of the viruses
detected in the Edinburgh cohort remained and was also
distinct from all CVA6 variants associated with aHFMD
elsewhere (Finland, Taiwan, Japan and China; Fig. 1a).
Variants from the USA, Spain and France were shown
previously to be distinct (Sinclair et al., 2014).
To investigate sequence relationships in other parts of the
genome, nucleotide sequences were obtained from the
3Dpol region, representing the coding region furthest away
from VP1, as well as VP4 and the 59 UTR. The dataset was
supplemented by 15 (near-)complete genome sequences of
CVA6 variants from the UK (n512) and Finland (n53). In
the 3Dpol region, sequences fell into eight primary clades,
each with 100% bootstrap support (Fig. 1b). Following the
practice of previous analyses of recombination in entero-
viruses (McWilliam Leitch et al., 2009, 2012), variants were
assigned into RF-A to -H based on 3Dpol phylogeny (and
coloured from blue to red; RF-I was assigned to the
outgroup sequence of the prototype CVA6 strain isolated
in 1949). A large number of phylogeny differences were
apparent between this tree and the tree from VP1.
3Dpol region sequences from the Edinburgh 2014 cohort
fell into a clade (RF-H) distinct from all other CVA6
strains characterized to date, including variants collected
from Edinburgh before the outbreak and variants asso-
ciated with previous aHFMD outbreaks in Finland, Japan
and Taiwan. As previously observed for other enterovirus
serotypes (McWilliam Leitch et al., 2009, 2010, 2012), CVA6
RFs possessed 3Dpol sequences that were interspersed with
corresponding sequences from other EV-A serotypes (Fig. 2
and Fig. S1, available in the online Supplementary Material),
which contrasts with their consistent grouping by serotype
in the structural gene region. Despite this, none of the
eight CAV recombination groups identified in the current
study shared 3Dpol region sequences with other species A
serotypes sequenced in this region.
The occurrence of recombination in the NS genome region
was demonstrated by a marked rise in segregation score
(indicating non-concordance of phylogeny positions with
group assignments) at the end of VP1 and towards the start
of VP4 (Fig. 2b). Intriguingly, the only exception was
CAV16 which, despite extensive sampling and availability
of multiple complete genome sequences, remained almost
entirely monophyletic throughout the genome apart from
the 59 end of the 59 UTR (Fig. 2a). A bootstrap-supported
clade containing all but one CAV16 sequence [the prototype
sequence with GenBank accession number AY421764
(Gdula isolate)] was clearly evident in the 3Dpol region
distinct from all other variants (Fig. S1). In contrast to the
NS gene region, the phylogeny of VP4/2 and the 59 UTR
E. Gaunt and others
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was broadly consistent with VP1 (Fig. 1c, d). The main
difference was between the grouping of RF-E with members
of RF-A and -H (both associated with HFMD) in VP1, but
its outlier position in 59 UTR and VP4/2.
The existence of recombination between genome regions
was also demonstrated through comparison of pairwise
distances between sequences in VP1 and those in 3Dpol (x-
and y-axes in Fig. 3, respectively) as previously performed
for EV71 (McWilliam Leitch et al., 2009). Within the RF-A
group, most sequence distances in the two genome regions
were comparable and a plot of pairwise distances fell largely
on a straight line, reflecting similar degrees of divergence in
the two genome regions (Fig. 3a). There were, however,
a number of exceptions, with some variants being less
divergent in 3Dpol than would be expected from their
degree of sequence divergence in VP1. These may represent
within-group recombinants, in which a number of RF-A
variants recombined with each other, acquiring less diver-
gent NS gene sequences than their sequences in VP1.
Further comparison of VP1 and 3Dpol region sequences
between RF-A and -H, and between RF-H and other recom-
bination groups, demonstrated that each possessed far more
divergent 3Dpol sequences than would be expected based on
VP1 pairwise distances (Fig. 3b). This was consistent with
numerous acquisitions of NS gene regions from other EV-A
species. The only exception was between RF-H and -G,
where mean sequence divergence in VP1 (0.069) was
comparable with that in 3Dpol (0.058), implying that these
two genome regions have co-diverged for a considerable
time. The reason why these are classified as different
recombination groups is explained below.
Reconstructing the timescale of specific
recombination events in CVA6
To investigate when recombination groups of CVA6 first
appeared, sequences from the VP1 region were analysed by
Markov chain Monte Carlo (MCMC) analysis using sample
dates to reconstruct a temporal phylogeny (Fig. 4). The
substitution rate of CVA6 VP1 sequences was estimated at
4.261023 substitutions site21 year21 (2.8–5.861023 high-
est posterior density interval), comparable with that of EV71
and other species A serotypes in previous analyses (Lukashev
et al., 2014; McWilliam Leitch et al., 2009). Substitution
rates were relatively uniformly distributed amongst different
lineages in the VP1 tree (Fig. S2).
In the more recent evolution of CVA6, approximate dates
of when recombination events must have occurred could
be inferred from the temporal phylogeny (Fig. 4), in which
the recombination groups of individual lineages were
inferred in a reconstruction in which the fewest number of
recombination events occurred (indicated by line colour).
Whilst the small number of CVA6 variants isolated before
2008 precluded detailed reconstruction of earlier recomb-
ination events, the reconstruction nevertheless indicated that
RF-A had a relatively long evolutionary history, with the
main clade (excluding the earliest isolate dated from 2003;
GenBank accession number AB779616) originally emerging
between 1994 and 2000. Several recombination groups (RF-
E, -F, -G and -H) subsequently emerged within this clade,
presumably the results of separate recombination events with
other species A serotypes over the past 10 years. The
recombination events that generated RF-E and -F could be
dated to ~3–5 years ago. The appearance of RF-H (or at least
the variants found in Edinburgh) was the most recent (2.5
years), consistent with the limited sequence heterogeneity
between VP1 sequences in this RF.
The deeper evolutionary history of CVA6 was more difficult
to reconstruct because of very limited sampling and a
paucity of characterized, more divergent CVA6 variants.
There were indeed many similarly parsimonious recom-
bination histories to account for the existence of RF-B to -D
and the presence of the 2003 outlier RF-A variant, GenBank
accession number AB779616 (which may conceivably have
originated through a parallel recombination event). For
these reasons, lineages reconstructed before the origin of the
main RF-A clade were designated ‘Undetermined’.
Mapping recombination breakpoints
A conceptual problem with determining where recom-
bination occurred in the evolution of enterovirus RFs is the
lack of any reference, non-recombinant sequences with
which to compare them. The past evolution of EV-A was
modular, and multiple occurrences of recombination were
evident from numerous incompatibilities in structural and
NS gene phylogenies in all extant variants (Fig. 1a, b).
Consequently, there were no non-recombinant sequences
of CVA6 with which to map breakpoints in RF-H. However,
a broad guide as to where recombination typically occurs is
provided by the TreeOrder scan of CVA6 sequences (Fig.
5a), in which sequences were colour coded by recombin-
ation group (RF-A to -H) and their tree positions recorded
across the genome.
The analysis was based on available CVA6 complete
genome sequences and those of representative sequences
Fig. 1. Phylogeny of CVA6 variants in different genome regions. Maximum-likelihood tree of (a) VP1 [positions 2430–3267
numbered using the reference CVA6 sequence, Gdula (GenBank accession number AY421764)], (b) 3Dpol (positions 6245–
6988), (c) 59 UTR (positions 24–752) and (d) VP4/partial VP2 (positions 753–1187). Trees were reconstructed using optimal
substitution models: Kimura two-parameter (K2P)+invariant sites (I) for VP1; K2P+I+gamma distribution (C) for 3Dpol;
K2P+I for 59 UTR and K2P+C for VP4/2. Trees were rooted with the prototype sequence, GenBank accession number
AY421764 (not shown). Bootstrap resampling (100 replicates) was used to determine robustness of groupings; values of
¢70% shown. Sequences were coloured according to their recombination group assignments based on 3Dpol phylogeny.
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from each of the recombination groups represented by
samples from Edinburgh and Finland characterized in the
current study (RF-A, -F, -G and -H). Sequences throughout
3B, 3C and 3Dpol (including the fragment used for RF
assignments; shown between vertical dashed lines) consis-
tently grouped by their recombination groups assignment
(a) 3Dpol
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Fig. 2. Tree positions (TreeOrder scan) of species A serotypes across the genome. (a) Tree positions represented on the x-axis
of available complete genome sequences of EV-A, including CVA6 genomes obtained in the current study. Sequences of
different EV types are coloured as labelled on the left-hand y-axis. The analysis excluded the more divergent EV76, EV89–91
and other simian-derived types, with the trees rooted using the poliovirus type 3 reference sequence, Leon (GenBank accession
number K01392, labelled PV3-OG). Trees were reconstructed from sequential 300-base fragments of the EV-A sequence
alignment, incrementing by 30 bases between trees. Groupings are based on clades showing ¢70% bootstrap support. (b)
Correspondence between the phylogeny of sequential fragments through the enterovirus genome with their type assignments,
scored from 0 (complete concordance) to 1 (no association) as described previously (Simmonds & Welch, 2006). An
enterovirus genome diagram drawn to scale is included to indicate positions where segregation changes occurred. Sequence
positions are numbered relative to the poliovirus type 3 Leon sequence outgroup (GenBank accession number K01392).
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with zero segregation scores (Fig. 5b). There were, however,
some minor changes in tree order between clades in this
region. Upstream, RF-A and -E disintegrated in the 3A
region with RF-E variants becoming embedded within RF-
A, followed by several other recombination groups around
the 2B/2C junction.
As an alternative way to visualize sequence relationships,
sequence alignments were scanned to identify regions of
the genome where sequence divergence became greater
than in VP1. This analysis method was developed from the
results of the dot-plot in which divergence in VP1 and
3Dpol was compared (Fig. 5b). This demonstrated ~3.5
times greater divergence between RF-H and other recom-
bination groups in 3Dpol than in VP1, indicative of
recombination. This analysis was extended by comparing
ratios of VP1/3Dpol divergence in successive fragments
across the genome to identify where changes in ratios
occurred and thus identify recombination breakpoints (Fig.
6). In the case RF-E, -F, -G and -H, temporal reconstruction
of VP1 sequences predicted that RF-A was ancestral to them
(Fig. 4) and that they likely originated through separate
recombination events. Divergence scans comparing RF-A
with RF-F and -H confirmed this hypothesis (Fig. 6a),
with divergence ratios close to 1 throughout the 59 UTR,
structural gene region and 2A, but steep increases in
divergence relative to that of VP1 around positions 3900
and 4400 (both within 2B or at junctions with 2A and 2C).
These localize likely recombination events with other
(uncharacterized) EV-A variants at these genome positions.
Sequence relationships with RF-E were more complex,
indicative of multiple recombination events. Sequences
between RF-A and -E were shared in VP3, VP1 and 2C,
whilst the 59 UTR, VP4 and VP2 were divergent. Further
recombination events were predicted to yield divergent 2A
and 2B genes, and a breakpoint within 3A was also apparent,
which resulted in a high ratio for the rest of the genome
downstream of this point. The high ratios observed in
VP4/2 and the 59 UTR were reflected in their outlier posi-
tions on phylogenetic comparisons from RF-A sequences
(Fig. 1c, d).
A complex relationship between RF-G with RF-A and -H
was also identified using this analysis (Fig. 6b). Comparing
RF-G with RF-A and -H revealed a breakpoint at around
position 3500 (within 2A), but in the case of RF-H, ratios
returned to ~1 beyond position 4200 (2B/2C junction).
Separate BLAST analysis of the 300-base segment within this
inserted region of RF-G (positions 3850–4150) failed to
identify any closely related sequences amongst other species
A serotypes (minimum divergence of 15%; data not shown).
RF-G is therefore effectively a divergent version of RF-H
throughout most of the genome (as indicated in the dot-
plot), but with an insertion of a novel, NS gene region
between VP1 and 3Dpol.
Association of recombination group with clinical
presentations
The current study obtained complete genome sequences
and paired VP1/3Dpol sequences from a large number of
CVA6 variants from Edinburgh and Finland, allowing
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Fig. 3. Comparison of pairwise distances in VP1 and 3Dpol between and within recombination groups. Comparison of
divergence between VP1 and 3Dpol regions (a) within recombination groups, and (b) between RF-H and other recombination
groups. Axes depict nucleotide sequence divergence (uncorrected p distances) in the two genome regions.
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associations between recombination group and clinical
presentations to be compared. Our search of GenBank and
PubMed databases identified four other studies from
Finland (O¨sterback et al., 2014), Taiwan (Chen et al.,
2012; Chung et al., 2013) and Japan (Fujimoto et al., 2012)
in which nine complete genome sequences were obtained
from CVA6 infections with clinical descriptions (Table 1).
Although comparing clinical descriptions from different
sources was problematic, it was possible to broadly divide
presentations into three categories: (1) herpangina and
other non-HFMD presentations; (2) aHFMD with lesions
extending to the hands, feet and perioral area, often clinic-
ally resembling chickenpox and being occasionally asso-
ciated with onychomadesis (nail loss); and (3) extensive
vesicular rash on the arms, legs and trunk, clinically
resembling either eczematous dermatitis or eczema herpet-
icum (also termed eczema coxsackium; Mathes et al., 2013)
and occasionally being associated with onychomadesis.
Although numbers were small, RF-A, along with RF-G,
showed a strong association with aHFMD that contrasted
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Fig. 4. Inferred timescale for the recent evolution of CVA6. Temporal reconstruction of recombination events in CVA6 using a
time-correlated MCMC phylogeny reconstruction of VP1 sequences using the prototype sequence, GenBank accession
number AY421764, as an outgroup (not shown). Recombination groups in each lineage are indicated by branch colours. The
tree is plotted on a linear timescale, with nodes labelled with inferred dates of lineage splits (in years before present). Grey bars
show 95% highest posterior density intervals for node date estimates.
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with presentations of herpangina of RF-B and -E. Of note
were the six cases of eczema herpeticum in those infected
with RF-H – a presentation unusual or absent for other
recombination groups. However, whilst we noted these
associations, it was not possible to perform formal statis-
tical significance testing of differences in clinical outcomes
between RFs because infections were not phylogenetically
or epidemiologically independent.
DISCUSSION
Recombination in CVA6
The variability in phylogeny relationships between CVA6
variants in different genome regions (Figs 1, 3 and 4) is
indicative of the occurrence of multiple recombination
events between the structural gene region and other parts
of the genome. These observations are consistent with a
model of the modular evolution of enteroviruses, in which
the diversification of the capsid gene, which determines
serological properties (Lukashev, 2005; Oberste et al.,
2004a; Santti et al., 1999), is largely uncoupled from that of
NS genes and the 59 UTR (Lukashev, 2005; Lukashev et al.,
2005; McWilliam Leitch et al., 2009; Simmonds, 2006).
Individual serotypes, such as echoviruses E30 and E11 in
EV-B species and EV71 in EV-A species, have been docu-
mented to periodically exchange entire or near-complete
NS gene regions with other enteroviruses; in E30, a regular
succession of different recombination groups appeared
throughout Northern and Western Europe over a 10-year
study period with particularly dramatic changes in recom-
bination group frequencies coinciding with peaks in its 4–5
year incidence cycle (Bailly et al., 2009; McWilliam Leitch
et al., 2009). Other serotypes, such as E6, E9 and E11
echoviruses, showed successions of recombination groups,
but with different dynamics and periodicities (Cabrerizo
et al., 2014; McWilliam Leitch et al., 2010). In our inves-
tigation of EV71 recombination, we found a more rigid
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and longer term association of specific genogroups with
individual 3Dpol clades; thus genogroups B1, B2, B3 and
B4/B5 were associated with RF-E, -D, -G and -A, respect-
ively, whilst C1, C2, C3, C4 and C5 were predominantly
associated with RF-W, -V, -L and -T (fig. 1 in McWilliam
Leitch et al., 2012). These longer term linkages in EV71
contrasted with much more frequent recombination events
amongst species A serotypes, CAV2, CAV4 and CAV10
(Lukashev et al., 2014). Although we lack sufficient sample
numbers to estimate recombination half-lives of CVA6, the
occurrence of numerous recombination events in the RF-A
clade within the past 10 years (Fig. 4) demonstrates rates
comparable with other EV-A serotypes.
These inter-serotype recombination rates contrast with the
low frequency reported for CAV16. In the analysis of
available complete-genome sequences largely originating
from China and elsewhere in East Asia, all variants (except
the prototype isolate, G-10 isolated in 1953) grouped
together throughout the NS region (Fig. 2a) and formed a
single recombination group in the 3Dpol region (Fig. S1).
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The only exception was the sequence of GenBank accession
number EU812514, ostensibly isolated in China in 2008,
but which was 99.8% identical in sequence to the proto-
type G-10 and is a likely laboratory contaminant or a
laboratory acquired infection. Further CAV16 sequences
characterized from Russia (n58) and Ukraine (n51) also
fell into this group (Lukashev et al., 2014). Whilst this
particular recombination group of CAV16 has clearly
persisted for many years and is geographically widespread,
analysis of the existing sequences dataset of other CAV16
variants (isolated in Finland, South Africa, Netherlands,
Spain) demonstrates the presence of five further recom-
bination groups distinct from the main group (McWilliam
Leitch et al., 2012). Whilst limited geographical sampling
has clearly led to underestimates of the number of recom-
bination groups of CAV16, existing data point towards
substantial differences in recombination frequencies between
different enteroviruses, even within the same species, for
reasons that remain unclear (Lukashev et al., 2014).
The temporal reconstruction of the recent evolutionary
history of CVA6 allowed the timing of recombination
events to be, at least in part, reconstructed. This analysis
was naturally limited by the available sampling, and clearly
the origins of RF-B, -C and -D that possess more divergent
VP1 sequence cannot be satisfactorily reconstructed at pres-
ent. However, for viruses within the main VP1 clade, the
most parsimonious interpretation of the distribution of
recombination groups was that RF-A was the ancestral form,
and that RF-E, -F, -G and -H have emerged more recently
following separate recombination events at various times
in the past 5–10 years. Being able to infer direc-
tionality greatly assists the reconstruction of the actual
recombination events that generated these more recently
appearing CVA6 variants (Fig. 6). Whilst RF-F and -H
appear to have originated through single recombination
events with breakpoints in the 2A/2B region (Fig. 6), two or
more events could be inferred for RF-G and -E. The position
of one of the breakpoints in RF-E within the VP3 gene
appears to contrast with previous analyses that have
documented the rarity of recombination events between
serotypes in the structural gene region (Cuervo et al., 2001;
Oberste et al., 2004b; Simmonds, 2006). However, capsid
gene sequences either side of the breakpoint are both of
CVA6 and the recombination events likely represent a
further example of an intra-serotype recombination that has
been documented in other enteroviruses (Costa-Mattioli et
al., 2003; Oberste et al., 2004b).
The reconstruction of recombination events also led to a
number of interesting reinterpretations about CVA6 disease
associations. Most importantly, if the evolutionary history of
RF-A extends back to before 2000, as implied by the most
parsimonious interpretation of the temporal phylogeny (Fig.
4), then it is unexpected that no cases of aHFMD earlier than
those first described in 2008 (O¨sterback et al., 2009) have
been recorded. It is possible that RF-A infections were
initially rare, remaining undetected or not sufficiently
characterized clinically until their distribution increased
to a point where the change in disease presentations was
recognized. Alternatively, RF-A may have originated and
spread in a geographical region with limited clinical/virolo-
gical surveillance and where changes in clinical presentation
of CVA6 infections were unrecorded. The other possibility is
that the more divergent 2010 isolate, GenBank accession
number JQ946053, had independently acquired an RF-A-
like NS structural gene; this would push forward the
common ancestor of the main group of RF-A variants to
2004, more consistent with its clinical emergence. Such
independent acquisition seems similarly likely for the 2003
isolate, GenBank accession number AB779616, that groups
closest with the RF-B variant, GenBank accession number
AB779614, in VP1 (Figs 1a and 5).
There is a similar possible reinterpretation of the evolu-
tionary age of RF-H, as evidently viruses with NS region
sequences matching this recombination group must have
existed before 2013 to account for their presence in the
evolutionary history of RF-G (through a likely second
recombination event). Again, the non-detection of RF-H
prior to 2013 may reflect its rarity and lack of surveillance
rather than non-pathogenicity. Clearly, more extensive
sampling and assignment of recombination groups to a
Table 1. Association of recombination forms with clinical presentation
See main text for definitions of the clinical presentation groups.
Recombination group Herpangina, other AHFMD Ecezema herpeticum
RF-A 1 23 (4)* 2 (1)
RF-B 1 (1) 1 0
RF-C 0 0 0
RF-D 0 0 0
RF-E 3 (3) 0 0
RF-F 0 1 0
RF-G 0 4 1
RF-H 0 2 6
*Additional examples within the total derived from published descriptions shown in parentheses.
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wider range of CVA6 variants is necessary to understand
more about the emergence of this and other CVA6 recom-
bination groups.
Viral determinants of CVA6 clinical phenotypes
There are few, if any, models in which potential differences
in disease association between CVA6 variants (or those
of any other serotype) can be investigated experimentally.
However, some limited conclusions can be drawn by com-
paring sequence relationships of CVA6 variants associated
with differing clinical outcomes. Based on partial VP1
sequences, most studies have found evidence for often distinct
clusters of variants associated with aHFMD, although com-
parisons of sequences from different studies demonstrate
little consistent grouping of aHFMD-associated cases between
different geographical regions (Chen et al., 2012; Chung et al.,
2013; Di et al., 2014; Huang et al., 2013; Lu et al., 2012;
Montes et al., 2013; O¨sterback et al., 2009; Puenpa et al.,
2014). These comparisons have been problematic, with often
only extremely short VP1 partial sequences being available.
It was also difficult, a priori, to know whether differences in
VP1 sequences are related to the phenotypic change in
CVA6 or whether changes elsewhere in the genome are
responsible, such as the 59 UTR or replication-associated
genes in the NS region. This difficulty is heightened by the
occurrence of recombination in CVA6 genomes that breaks
linkages between VP1 lineage with mutations elsewhere in
the genome that may influence viral phenotype.
However, by comparing sequences in other parts of the
genome (59 UTR, VP4 and 3Dpol), it was possible to make
some inferences over which genome regions are most
closely associated with clinical phenotypes. Despite the
variability of VP1 sequences, all variants associated with
aHFMD after 2008 characterized to date worldwide fell
into RF-A, including most Edinburgh samples collected
before 2014. Cases of eczema herpeticum reported from
Edinburgh in 2014 (Sinclair et al., 2014) fell into a novel
clade, RF-H. The significant differences between recom-
bination group and clinical presentations (Table 1) were
supported by individual observational studies. Taiwanese
cases associated with herpangina were consistently RF-E
(GenBank accession numbers JQ94600–JQ94602), whilst
those collected in 2010–2011 and associated with HFMD
(GenBank accession numbers JQ94603–JQ94605 and
JN582001) were RF-A. A differentiation of HFMD-asso-
ciated variants in Japan from those collected pre-outbreak
was similarly evident. Although lacking 3Dpol sequences,
CVA6 variants from 2011 that were not associated with
HFMD possessed VP1 sequences closely similar to RF-D
and -C (GenBank accession numbers AB779617 and
JQ964234, respectively). In contrast to the association of
RF-A and -H with aHFMD, no associations between
clinical presentations and 59 UTR or VP4 region phyl-
ogenies were apparent.
Whether the RF-H variants detected in Edinburgh in 2014
are more geographically widespread requires further genetic
characterization of NS gene regions of CVA6 isolates from
other geographical regions; recombination group cannot be
reliably predicted from VP1 phylogenies. However, none of
the published VP1 sequences fall into the clade formed by
recent Edinburgh variants in this genome region (Fig. 1a),
suggesting a current, relatively limited geographical distri-
bution. Further work is clearly required to better character-
ize any possible clinical or epidemiological differences
between RF-A and RF-H CVA6 variants and determine
whether or when RF-H replaces RF-A globally. This might
be performed by the consortium of clinical laboratories in
Europe, Asia and Australia that previously documented the
recombination dynamics of other enteroviruses (Cabrerizo
et al., 2014; McWilliam Leitch et al., 2009, 2010, 2012).
Further samples and surveillance data are potentially avail-
able from larger reference laboratories, such as the US and
European communicable disease centres. Such studies may
contribute to a better understanding of the driving forces
behind such replacement processes, such as the appearance
of RF-A in 2008, and the numerous examples amongst EV-B
serotypes, and their relationships with clinical disease and
herd immunity. These are crucial for gaining a better
understanding of the pathogenesis of enterovirus infections
and their variability in clinical phenotypes.
METHODS
Clinical samples. Twelve samples were obtained from patients
presenting with eczema herpeticum as described previously (Sinclair
et al., 2014), along with other samples from Edinburgh patients with
aHFMD infected with CVA6 (Harvala et al., 2014). Fifteen samples
from a previous CVA6 outbreak in Finland (O¨sterback et al., 2009)
were also analysed.
PCR and nucleotide sequencing. Samples of vesicle fluids (from
eczema herpeticum/aHFMD cases) or cerebrospinal fluid were
extracted using a QIAamp MinElute Virus Spin kit (Qiagen) according
to manufacturer’s instructions. A one-step reverse transcription/first-
round PCR was undertaken. Each 20 ml reaction contained 10 ml
SuperScript III One-Step RT-PCR 26Master Mix (Invitrogen), 0.8 ml
SuperScript III RT/Platinum Taq High Fidelity Enzyme Mix
(Invitrogen), 1 ml each forward and reverse outer primers for VP4,
VP1, 3Dpol or 59 UTR region amplification (Table 2), and 6 ml nucleic
acid. Cycling conditions for VP1 amplification were 43 uC for 60 min,
then 20 cycles of 53 uC for 1 min and 55 uC for 1 min, one 70 uC hold
for 15 min, one 94 uC hold for 2 min, then 40 cycles of 94 uC for 30 s,
45 uC for 30 s and 68 uC for 1 min 45 s, followed by a 68 uC hold for
5 min. Cycling conditions for VP4, 3Dpol and 59 UTR were slightly
modified so that the 45 uC annealing temperature was raised to 50 uC,
as described previously (Leitch et al., 2009). The 20 ml second-round
nested PCR contained 4 ml reaction buffer (Promega), 0.2 ml dNTPs,
1 ml each forward and reverse VP1 or VP4 inner primers, 0.1 ml Taq
polymerase (Promega) and 1 ml first-round product. CVA6-specific
PCR used VP1-specific primers (Table 2).
Complete genome sequencing. Complete genome sequencing of
15 CVA6 strains was carried out at the MRC University of Glasgow
Centre for Virus Research using a metagenomic approach on the
Illumina MiSeq platform. Extracted RNA was converted to double-
stranded cDNA using a Maxima First Strand cDNA Synthesis kit
(Thermo Scientific) and a Second Strand cDNA Synthesis kit (NEB).
Library preparation was carried out using Nextera XT (Illumina).
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Alignment files and consensus sequences were generated using Tanoti
(http://www.bioinformatics.cvr.ac.uk/Tanoti/index.php).
Sequence alignment and strain analysis. Forward and reverse
sequence reads were reconciled and aligned in the SSE 2.1 sequence
editor package (www.virus-evolution.org) (Simmonds, 2012).
Datasets included all available complete genome sequences of EV-A
types, although due to their number, EV71 sequences were excluded if
,3% divergent over the genome from other EV71 variants.
Phylogenetic trees were reconstructed by the maximum-likelihood
method using optimal nucleotide substitution models identified in
ModelTest as implemented in the MEGA6 package (Tamura et al.,
2013). Recombination analysis used the programs Sequence Distance
and Grouping Scan in the SSE package (Simmonds, 2012).
All sequences obtained in the study, along with geographical and date
information on published sequences included in the analysis, are
listed in Table S1.
A Bayesian MCMC method implemented in BEAST 1.74 (Drummond
et al., 2006) was used to estimate temporal phylogenies and rates of
evolution (Drummond & Rambaut, 2007). VP1 region sequences
were analysed using constant and exponential population sizes as
priors with a chain length of 50 million and a relaxed log-normal
molecular clock model that allowed evolutionary rates to vary
between lineages. All other parameters were optimized during the
burn-in period. Substitution rates and phylogenies were comparable
between outputs generated by the two different priors; the results
from exponential population sizes were used for the analysis. Output
from BEAST was analysed using the program TRACER (http://beast.bio.
ed.ac.uk/Tracer) and through construction of a maximum clade
credibility tree using TreeAnnotator/FigTree.
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